STOCK TITAN

Resmed SEC Filings

RSMDF OTC Link

Welcome to our dedicated page for Resmed SEC filings (Ticker: RSMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Resmed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.

Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Resmed's regulatory disclosures and financial reporting.

Rhea-AI Summary

The Vanguard Group filed an amended Schedule 13G reporting a passive stake in ResMed Inc. (RMD). As of 09/30/2025, Vanguard reported 20,007,417.40 shares beneficially owned, representing 13.66% of the class. The filing notes the holdings are in the form of depository receipts.

Vanguard reported 0 shares with sole voting power and 1,834,309.40 with shared voting power. It reported 17,643,708.00 shares with sole dispositive power and 2,363,709.40 with shared dispositive power. Vanguard certified the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. Its clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

The Vanguard Group filed an amended Schedule 13G reporting a passive stake in ResMed Inc. (RMD). As of 09/30/2025, Vanguard reported 20,007,417.40 shares beneficially owned, representing 13.66% of the class. The filing notes the holdings are in the form of depository receipts.

Vanguard reported 0 shares with sole voting power and 1,834,309.40 with shared voting power. It reported 17,643,708.00 shares with sole dispositive power and 2,363,709.40 with shared dispositive power. Vanguard certified the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. Its clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

How many Resmed (RSMDF) SEC filings are available on StockTitan?

StockTitan tracks 121 SEC filings for Resmed (RSMDF), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Resmed (RSMDF)?

The most recent SEC filing for Resmed (RSMDF) was filed on October 30, 2025.